Launches Dapagliflozin Tablets in the United States - Lupin Ltd

Code BSE: 500257 NSE:

Lupin Launches Dapagliflozin Tablets in the United States Lupin Limited yesterday announced the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Farxiga for the indications in the approved labeling